INDEFI’s Post

[NEWS] CAPZA partners with IMDEV to accelerate its development in medical imaging Created in 2019, IMDEV (Imagerie Développement) is a leading medical imaging group in France with nationwide coverage, that aims to offer quality care and access to medical services, especially in underserved areas. With a fleet of 90 MRI and CT scanners, 3 PET scanners and 6 Gamma cameras, the Group operates almost 120 centers and works with 200 radiologists across France. The group is also positioning itself as an innovative forerunner in the medical imaging industry by introducing Artificial Intelligence to improve diagnostics and optimize processes. 🎯 With CAPZA and Bpifrance Large Cap as minority investors, IMDEV’s objective is to reinforce its status as a leader in France by expanding organically as well as through an ambitious, targeted acquisition strategy. ➡️ CAPZA acquires a reference minority stake through its Flex Equity Mid-Market expertise, which aims at supporting mid-cap companies in accelerating their growth and helping them meet the challenges of #decarbonation. This is the 5th transaction of its Flex Equity Mid-Market II Fund in 18 months. Many thanks to IMDEV-Imagerie Développement, Fréderick Breittmayer and Alexandre Azouaou for trusting us to support the Group's next stage of #growth 🚀 👏 Guillaume Basquin, Jess Wizman, Mary Laroche, Thomas Lavack Read more 👉  https://bit.ly/42NCFXl #Investment #PrivateEquity #Healthcare

🚀 Edwards keeps M&A streak going with JC Medical Acquisition! Edwards Lifesciences has just made a very interesting move by acquiring JC Medical, Inc. and its innovative J-Valve system. This acquisition includes all intellectual property and commercial rights related to J-Valve, a pioneering transcatheter aortic valve replacement (TAVR) system. This strategic decision continues Edwards' trend of key acquisitions in the MedTech space, including recent acquisitions of JenaValve, Endotronics and Innovalve Bio Medical. The J-Valve system comes with an FDA breakthrough device designation, showing its massive potential for treating severe native aortic regurgitation (AR) and AR-dominant mixed aortic valve disease. Known for its minimally invasive, transfemoral procedure, J-Valve eliminates the need for open-heart surgeries. This advancement could be a game-changer for those affected by these conditions, which are often underserved by current treatments in the US. With Edwards' backing, including an equity investment of $25 million in Genesis MedTech, the future looks bright for J-Valve's global impact. What do you think this means for the future of TAVR systems and heart valve treatments in general? Share your thoughts below or visit www.rinconsearchgroup.com to learn more. #MedTech #HealthcareInnovation #JValve

STAAR Surgical Reports Second Quarter 2024 Results LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second quarter ended June 28, 2024. Second Quarter 2024 Overview Net sales up 7% to $99.0 million and up 9% to $100.4 million in constant currency ICL sales up 7% to $99.4 million and units up 3% Gross margin at 79.2% vs. 76.6% year via Business Wire Health: Medical Devices News

Check the latest divestment news from the industry for my followers ⤵️ 📣 Integra to buy J&J's Acclarent for $275M | MedTech Dive 📰 🎙️Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures. 🤔 It goes to show it's not always the top 🔟 globals 🌐 swallowing the smaller players sometimes the big guys need to take stock 📉 and carve off portfolios to keep at the head of their game 🔺 and "bargains" 💰 to be had for the next tier on the hunt for a solid M&A deal to strengthen their offering 💪. #latestnews #medicaldevice #healthcare #medtech #Acclarent #Integra #entsurgery #M&A #divestment

Graft Delivery Device Market, Global Outlook and Forecast 2024-2030 || Download FREE Sample of this Report https://lnkd.in/dscw6jQE The global Graft Delivery Device market was valued at US$ 579.57 million in 2023 and is projected to reach US$ 960.92 million by 2030, at a CAGR of 7.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. by Company: Arthrex Stryker Medtronic Nordson Corporation medmix Pinnacle Spine Group Kleiner Device Labs Get the Complete Report & TOC https://lnkd.in/dHR-2K3q CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: ( 1) 332 2424 294 /  91 8087042414 Follow Us On linkedin :- https://lnkd.in/d-gZVjNy #Graftdeliverydevice #Graft #Graftdeliverydevicemarketreport #Graftdeliverydevicemarketsize #Graftdeliverydevicemarketshare #grandresearchstore

Exciting news as we join Avation Medical's $22M Series C, led by ShangBay Capital and Asahi Kasei, including funding from Angelini Ventures, JobsOhio Growth Capital Fund, Arboretum Ventures, Tonkawa, Medtronic and Avestria Ventures. 💡 Thrilled about our investment in the FDA-approved wearable technology for overactive bladder (OAB): the Vivally System. With an 88% compliance rate, it uses smart technology in 30-minute sessions to reduce void episodes and improve patient well-being. A breakthrough in OAB treatment! Thomas Michael Thestrup, PhD, Principal at Angelini Ventures, expresses, "Avation Medical redefines OAB treatment. The patient-friendly, at-home Vivally System provides closed-loop neuromodulation without the need for medication or surgery when worn on the ankle." Kudos to Jill Schiaparelli, MBA and the Avation Medical team! 🎉 We're dedicated to shaping a future where healthcare is innovative, accessible, and patient-centric. 💙 Read more here https://lnkd.in/dy388YsW #healthtechinnovation #shapethefuture #connectedhealth 🚀

Good conversation about Medtech M&A trends and strategies at #LSXWorldCongress

Global #implantable #heart #pacemaker market size is expected to reach $6.18 Bn by 2028 at a rate of 4.9%, segmented as by product type, single chamber, dual chamber, biventricular Major companies operating in the implantable heart pacemaker market report are Medtronic PLC, BIOTRONIK Inc., Shree Pacetronix Ltd., St Jude Medical Inc., Sorin Group Read More @https://lnkd.in/gkPHEHmf #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel 

Acquisitions of the 𝐌𝐚𝐠𝐧𝐢𝐟𝐢𝐜𝐞𝐧𝐭 𝐒𝐞𝐯𝐞𝐧 in the medical ultrasound!   I previously wrote about the Magnificent Seven in the #medical #ultrasound. Historically ultrasound imaging has been one of the fastest growing imaging modalities. This high growth rate has made the ultrasound market a very attractive target for acquisition. For this post I thought to revisit the major #acquisitions of the Magnificent Seven over the years.   ① GE HealthCare - 1998: Acquired Diasonics Vingmed for $230M. - 2001: Acquired Kretztechnik for $145M. - 2021: Acquired bk medical for $1.45B. ② Philips - 1998: Acquired ATL for $0.8B. - 2001: Acquired Agilent Healthcare/HP Medical for $1.7B. ③ FUJIFILM Holdings America Corporation - 2012: Acquired Sonosite for $1B. - 2021: Acquired Hitachi Diagnostic Imaging for $1.6B. Hitachi itself had acquired Aloka in 2010 for $316M. ④ Canon Medical Systems Corporation - 2016: Acquired Toshiba Medical for $6B. ⑤ Mindray - 2013: Acquired Zonare for $105M. ⑥ Siemens Healthineers - 2000: Acquired Acuson for $0.7B. ⑦ Samsung Medison - 2010: Acquired Medison for $262M.   Today over 90% of medical ultrasound equipment market is dominated by the Magnificent 7. #mergerandacquisition #mna #marketshare   *Views and ideas are my own. The content that I provide here are intended to be educational only and are not financial advice. I have personal investment in several public and private tech and medtech companies namely GEHC, Clarius, and many others through ETF, but always encourage the readers to do their own research.